TrialThe Journal of infectious diseases2023

Viral Resistance Analyses From the Remdesivir Phase 3 Adaptive COVID-19 Treatment Trial-1 (ACTT-1).

Charlotte Hedskog et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.